
CZC-25146 hydrochloride
CAS No. 1330003-04-7
CZC-25146 hydrochloride( —— )
Catalog No. M19921 CAS No. 1330003-04-7
CZC-25146 is a selective LRRK2 inhibitor with IC50 of 4.76 nM/6.87 nM for wild type LRRK2 and G2019S LRRK2 respectively.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 101 | Get Quote |
![]() ![]() |
10MG | 178 | Get Quote |
![]() ![]() |
25MG | 296 | Get Quote |
![]() ![]() |
50MG | 443 | Get Quote |
![]() ![]() |
100MG | 645 | Get Quote |
![]() ![]() |
200MG | Get Quote | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameCZC-25146 hydrochloride
-
NoteResearch use only, not for human use.
-
Brief DescriptionCZC-25146 is a selective LRRK2 inhibitor with IC50 of 4.76 nM/6.87 nM for wild type LRRK2 and G2019S LRRK2 respectively.
-
DescriptionCZC-25146 is a selective LRRK2 inhibitor with IC50 of 4.76 nM/6.87 nM for wild type LRRK2 and G2019S LRRK2 respectively.
-
In VitroCZC-25146 (0.01-5 μM; 7 days) does not cause cytotoxicity in human cortical neurons, nor blocking neuronal development.CZC-25146 (0.01-5 μM; 2 days) potently attenuates G2019S LRRK2-mediated toxicity in primary rodent neurons in a concentration-dependent manner with an EC50 of ~100 nM.CZC-25146 (0.06-1000 nM) rescues LRRK2 G2019S-induced neurite defects in primary human neurons in a dose-dependent manner.CZC-25146 (14.3 and 28.6 μM; 48 h) markedly reduces The mutant AAT encoded by the Z allele (ATZ) polymer load and restores AAT secretion in iPSC-Hepatocyte, without compromising cell viability. Cell Cytotoxicity Assay Cell Line:Human cortical neurons Concentration:0.01, 0.1, 1 and 5 μM Incubation Time:7 days Result:Did not cause cytotoxicity in human cortical neurons at concentrations below 5 μM over a seven-day treatment in culture, nor did it block neuronal development.
-
In VivoCZC-25146 (1 mg/kg for i.v.; 5 mg/kg for p.o.; single dosage) exhibits relatively good pharmacokinetic properties and an extensive distribution throughout animal body following intravenous injection into mice.CZC-25146 (250 mg/kg; p.o.; 14 days) reduces the ATZ polymer levels in over expressing human polymeric ATZ mice. Animal Model:Male CD-1 mice Dosage:1 mg/kg for i.v.; 5 mg/kg for p.o.Administration:i.v. and p.o.; single dosage Result:Pharmacokinetic Parameters of CZC-25146 in male CD-1 mice.Animal Model:Genetically modified male mice (6 weeks; over expressing human polymeric ATZ) Dosage:250 mg/kg Administration:p.o.; 14 days Result:Dramatically and reproducibly reduced the ATZ polymer levels with an overall reduction from 60% in the control group to 37%
-
Synonyms——
-
PathwayAutophagy
-
TargetLRRK2
-
RecptorLRRK2 (G2019S) LRRK2 (WT)
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1330003-04-7
-
Formula Weight525
-
Molecular FormulaC22H26ClFN6O4S
-
Purity>98% (HPLC)
-
SolubilityDMSO: 15 mg/mL
-
SMILESCl.COc1cc(ccc1Nc1ncc(F)c(Nc2ccccc2NS(C)(=O)=O)n1)N1CCOCC1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Ramsden N et al. Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons. ACS Chem Biol. 2011 Oct 21;6(10):1021-8.
molnova catalog



related products
-
EB-42486
EB-42486 is an effective and highly selective inhibitor of G2019S-LRRK2 with an IC50 < 0.2 nM.
-
HG-10-102-01
HG-10-102-01 is an inhibitor of leucine-rich repeat kinase 2 (LRRK2 IC50 of 20.3 nM).
-
LRRK2-IN-1
A potent LRRK2 inhibitor with IC50s of 13 nM/6 nM for wild-type/G2019S mutant LRRK2 repectively (0.1 mM ATP in the assay).